1. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma 
Gail Shapiro, MDa, Louis Mendelson, MDb, Michael J. Kraemer, MDc, Mario Cruz-Rivera, PhD, MPHd, Karen Walton-Bowen, MSc, Cstatd, Joseph A. Smith, MDd 
Journal of Allergy and Clinical Immunology 
Volume 102, Issue 5, Pages (November 1998)
DOI: /S (98)
Copyright © 1998 Mosby, Inc. Terms and Conditions

2. Fig. 1
Mean change from baseline nighttime (top panel) and daytime (bottom panel) asthma symptoms scores during treatment weeks 0 to 12. *P ≤ .05 versus placebo; ‡P ≤ .01 versus placebo. BID, Twice daily.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) )
Copyright © 1998 Mosby, Inc. Terms and Conditions

3. Fig. 2
Mean change from baseline (± 95% confidence interval) in number of days bronchodilator (pMDI or nebulizer) was required over the 12-week treatment period. *P ≤ .05 versus placebo; †P ≤ .01 versus placebo. BID, Twice daily.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) )
Copyright © 1998 Mosby, Inc. Terms and Conditions

4. Fig. 3
Mean basal and ACTH-stimulated cortisol levels (± SD) at baseline and after the 12-week treatment period for each group. BID, Twice daily.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) )
Copyright © 1998 Mosby, Inc. Terms and Conditions